Omeros Corp (OMER) - Financial and Strategic SWOT Analysis Review

  • ID: 4281572
  • SWOT Analysis
  • 50 pages
  • GlobalData
  • Omeros Corporation
1 of 5

FEATURED COMPANIES

  • Protalex Inc
  • Seattle Genetics Inc
  • MORE
Omeros Corp (OMER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Omeros Corp (Omeros) is a biopharmaceutical company that discovers, develops and commercializes small-molecule and protein therapeutics for large-market and orphan indications. The company’s pipeline products include Omidria, a phenylephrine and ketorolac injection and its product candidates are intended for the treatment of ophthalmological, arthroscopic, urological and other surgical procedures including thrombotic microangiopathies, complement-mediated glomerulopathies, addictive and compulsive disorders, and others. Its preclinical product candidates are intended for treatment of bleeding disorders, alternative pathway disorders, central nervous system disorders, metabolic, oncologic, musculoskeletal and other disorders. Omeros is headquartered in Seattle, Washington, the US.

Omeros Corp Key Recent Developments

Aug 09, 2018: Omeros reports second quarter 2018 financial results
May 10, 2018: Omeros Reports First Quarter 2018 Financial Results
Apr 11, 2018: Omeros Announces Amendment of Credit Facility
Mar 01, 2018: Omeros Reports Fourth Quarter and Year-End 2017 Financial Results
Nov 09, 2017: Omeros Reports Third Quarter 2017 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Protalex Inc
  • Seattle Genetics Inc
  • MORE
Section 1 - About the Company
Omeros Corp - Key Facts
Omeros Corp - Key Employees
Omeros Corp - Key Employee Biographies
Omeros Corp - Major Products and Services
Omeros Corp - History
Omeros Corp - Company Statement
Omeros Corp - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis
Company Overview
Omeros Corp - Business Description
R&D Overview
Omeros Corp - SWOT Analysis
SWOT Analysis - Overview
Omeros Corp - Strengths
Omeros Corp - Weaknesses
Omeros Corp - Opportunities
Omeros Corp - Threats
Omeros Corp - Key Competitors

Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances
Omeros Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Omeros Corp, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Omeros Corp, Recent Deals Summary

Section 5 – Company’s Recent Developments
Aug 09, 2018: Omeros reports second quarter 2018 financial results
May 10, 2018: Omeros Reports First Quarter 2018 Financial Results
Apr 11, 2018: Omeros Announces Amendment of Credit Facility
Mar 01, 2018: Omeros Reports Fourth Quarter and Year-End 2017 Financial Results
Nov 09, 2017: Omeros Reports Third Quarter 2017 Financial Results
Aug 08, 2017: Omeros Reports Second Quarter 2017 Financial Results
Jun 29, 2017: Omeros Releases Statement in Response to Recent False Report
May 10, 2017: Omeros Reports First Quarter 2017 Financial Results
Mar 16, 2017: Omeros Reports Fourth Quarter and Year-End 2016 Financial Results

Section 6 – Appendix
Methodology
Ratio Definitions
About
Contact Us
Disclaimer

List of Tables
Omeros Corp, Key Facts
Omeros Corp, Key Employees
Omeros Corp, Key Employee Biographies
Omeros Corp, Major Products and Services
Omeros Corp, History
Omeros Corp, Subsidiaries
Omeros Corp, Key Competitors
Omeros Corp, Ratios based on current share price
Omeros Corp, Annual Ratios
Omeros Corp, Annual Ratios (Cont...1)
Omeros Corp, Interim Ratios
Omeros Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Omeros Corp, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Omeros Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Omeros Corp, Performance Chart (2013 - 2017)
Omeros Corp, Ratio Charts
Omeros Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Omeros Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Seattle Genetics Inc
  • Protalex Inc
  • Karyopharm Therapeutics Inc
  • Imprimis Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll